Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
Part of paid clinical trials in Jacksonville, Florida.
- Sponsor
- EMVision Medical Devices Ltd
- Study ID
- NCT06999122
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 22 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Brain Scan — DIAGNOSTIC_TESTThe EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head. The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues.
Study Details
The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available. EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.
Key Dates
- Start date
- Mar 26, 2025
- Status verified
- May 2025
- Primary completion
- Nov 1, 2026
- Completion
- Nov 28, 2026
Study Design
- Enrollment
- 300 participants (estimated)
Arms
- Arm: Intracranial Haemorrhage Group A
- Arm: Other Group BGroup B includes all patients enrolled in the study ultimately diagnosed with a condition other than intracranial haemorrhage, including ischaemic stroke, transient ischaemic attack, or any of a variety of stroke mimicking conditions.
Primary Outcome Measure
Demonstrate haemorrhage detection sensitivity >80% and specificity >80% [ Time Frame: <30 minutes from acute baseline CT/MRI ]
Central Contacts
- Christian Wight, PhD61 (0) 490 109 797
- Sadie Burnham7742078910
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Jacksonville | Jacksonville | Florida | 32224 | William Freeman, PhD (PRINCIPAL_INVESTIGATOR) |
| UTHealth | Houston | Texas | 77030 | Aaron Gusdon, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Jacksonville, FL
Related Studies
- Human-Machine System for the H2 Lower Limb ExoskeletonRecruiting · University of Houston · Houston, Texas
- Get With the Guidelines-Stroke RegistryRecruiting · American Heart Association · Dallas, Texas
- Neurologic Stem Cell Treatment StudyRecruiting · MD Stem Cells · Westport, Connecticut
- GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval StudyRecruiting · W.L.Gore & Associates · Tucson, Arizona